Clearside Biomedical
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 7.9m | 29.6m | 1.3m | 8.2m | <1m | 3.0m | 13.3m |
| % growth | 263 % | 275 % | (96 %) | 520 % | (93 %) | 438 % | 345 % |
| EBITDA | (17.9m) | (<1m) | (29.6m) | (23.1m) | - | - | - |
| % EBITDA margin | (227 %) | (2 %) | (2231 %) | (280 %) | - | - | - |
| Profit | (18.2m) | <1m | (32.9m) | (32.5m) | (38.8m) | (46.1m) | (52.6m) |
| % profit margin | (231 %) | 1 % | (2483 %) | (395 %) | (6999 %) | (1546 %) | (396 %) |
| EV / revenue | 14.7x | 4.5x | 14.4x | 5.4x | 136.2x | 25.3x | 5.7x |
| EV / EBITDA | -6.5x | -297.6x | -0.7x | -1.9x | - | - | - |
| R&D budget | 15.1m | 18.5m | 19.6m | 20.8m | - | - | - |
| R&D % of revenue | 191 % | 63 % | 1479 % | 253 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$4.0m | Series A | ||
N/A | Spinout | ||
$7.9m | Series A | ||
| N/A | $6.0m | Early VC | |
$16.0m | Series B | ||
$20.0m | Series C | ||
| N/A | N/A | IPO | |
* | $65.0m | Post IPO Debt | |
* | N/A | $15.0m | Post IPO Equity |
| Total Funding | $53.9m | ||
Related Content
Recent News about Clearside Biomedical
EditClearside Biomedical, Inc. is a biopharmaceutical company focused on developing and delivering innovative therapies to treat serious eye diseases. The company specializes in the suprachoroidal space (SCS) injection platform, which allows for precise drug delivery to the back of the eye, targeting the choroid and retina. This method helps in treating conditions that cause irreversible and debilitating visual impairments by compartmentalizing the drug away from nondiseased tissues, thereby enhancing efficacy and reducing side effects.
Clearside's primary clients include healthcare providers, ophthalmologists, and patients suffering from retinal diseases. The company operates in the biopharmaceutical market, specifically targeting ocular conditions. Clearside's business model revolves around the development, clinical testing, and commercialization of its proprietary SCS injection platform and associated therapies. Revenue is generated through product sales, licensing agreements, and partnerships with other pharmaceutical companies.
Clearside's innovative approach aims to address unmet medical needs in ophthalmology, providing more effective and safer treatment options for patients. The company's pipeline includes therapies for various retinal diseases, including uveitis, diabetic macular edema, and age-related macular degeneration.
Keywords: suprachoroidal space, ocular therapies, retinal diseases, drug delivery, biopharmaceutical, ophthalmology, innovative treatments, compartmentalized drug, visual impairments, Clearside Biomedical.